Illumina Expands Billion Cell Atlas with AI Drug Developers
Event summary
- Illumina adds three new members, including AI drug developer Formation Bio, to its Billion Cell Atlas alliance.
- The program has sequenced over 350 million cells, generating six petabytes of genomic data since its January 2026 launch.
- New partners will use the dataset to advance precision medicine by understanding cell-specific responses to genetic changes.
- Formation Bio aims to improve asset selection and clinical trial design using the Atlas's perturbation data.
The big picture
Illumina's expansion of the Billion Cell Atlas underscores the growing convergence of AI and genomics in drug discovery. By providing a comprehensive map of human disease biology, Illumina is positioning itself as a critical infrastructure provider for biopharma companies seeking to de-risk development pipelines. The addition of AI-native partners signals a strategic shift toward data-driven decision-making in therapeutic development.
What we're watching
- Data Utilization
- How effectively new partners leverage the Atlas to accelerate drug development timelines.
- Competitive Positioning
- Whether Illumina can maintain its lead in genomic data infrastructure amid rising AI-driven competition.
- Clinical Translation
- The pace at which insights from the Atlas translate into approved therapies, particularly for first-in-class drugs.
Related topics